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Brain and tumour blood ow can be measured noninvasively using arterial spin labelling (ASL) magnetic resonance imaging (MRI),
but reliable quantication in mouse models remains dicult. Pseudocontinuous ASL (pCASL) is recommended as the clinical
standard for ASL and can be improved using multiphase labelling (MP pCASL). ­e aim of this study was to optimise and validate
MP pCASL MRI for cerebral blood ow (CBF) measurement in mice and to assess its sensitivity to tumour perfusion. Following
optimization of the MP pCASL sequence, CBF data were compared with gold-standard autoradiography, showing close agreement.
Subsequently, MP pCASL data were acquired at weekly intervals in models of primary and secondary brain tumours, and tumour
microvessel density was determined histologically. MP pCASL measurements in a secondary brain tumour model revealed a sig-
nicant reduction in blood ow at day 35 after induction, despite a higher density of blood vessels. Tumour core regions also showed
reduced blood ow compared with the tumour rim. Similarly, signicant reductions in CBF were found in a model of glioma 28 days
after tumour induction, together with an increased density of blood vessels. ­ese ndings indicate that MP pCASL MRI provides
accurate and robust measurements of cerebral blood ow in näıve mice and is sensitive to changes in tumour perfusion.
1. Introduction
Reliable and accurate quantication of cerebral blood ow
(CBF) by noninvasive methods, such as magnetic resonance
imaging (MRI), is of critical importance in many neuropa-
thologies. ­e measurement of tumour blood ow, for ex-
ample, is key to both treatment planning and predicting
response. Tumour perfusion is widely used as an indicator of
tumour microenvironment, stage, and progression, and
greatly inuences treatment. Clinical studies have shown that
tumour perfusion and, consequently, oxygenation are highly
correlated with clinical outcome [1–3]. Critically, the in-
creased use of antiangiogenic drugs and vascular normalising
therapies in conjunction with radiotherapy to treat tumours
has resulted in a need for improved quantitative, noninvasive
imaging measurements of vascular parameters to monitor
treatment response.
­eMRI method arterial spin labelling (ASL) is often used
to image cerebral blood ow (CBF), as it requires no exogenous
contrast agent and is easily implemented on clinical scanners.
Moreover, this method can provide absolute quantitative
measures of blood ow, which are not readily obtained by other
modalities. Pseudocontinuous ASL (pCASL), in particular, has
been recommended as the methodology of choice for clinical
ASL [4], but no such recommendations currently exist for
mice. Importantly, many potential therapeutic strategies for
brain tumours are initially tested in mouse models. Conse-
quently, there is a need for accurate methods of measuring
preclinical brain and tumour blood ow, reecting those used
in the clinic, to enable assessment of likely therapeutic ecacy.
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Despite initial reports developing ASL in rodents [5, 6],
most implementations have focussed on clinical ASL. Many
challenges exist in the adaptation of pCASL MRI for pre-
clinical use, including higher blood flow velocities in the
feeding arteries, smaller brain size, susceptibility artefacts
from neighbouring air spaces, and B0 inhomogeneities in
high-field preclinical systems. Implementations of ASL in
mice have historically produced CBF values that are semi-
quantitative [7–9], single slice [10], or vary with the sequence
[11–13] and body position [14] used. Moreover, the mean
brain CBF values obtained are often unphysiologically high
(>200mL/100 g/min) [11, 15–17] and show little concor-
dance with gold-standard autoradiography measurements
(ca. 100mL/100 g/min) in the normal mouse brain [18–22].
+ese values may be influenced by the use of anaesthetics,
which at high concentrations can increase CBF dramatically
[23, 24]. Whilst some preclinical studies have validated their
ASL measurements using autoradiography [25–27] or mi-
crospheres [28], pCASL has not yet been validated in the
mouse brain. A previous implementation of pCASL to
measure CBF in mice not only showed clear advantages but
also showed a loss of inversion efficiency stemming from
phase offsets in the label-control acquisitions [12].
+e use of multiphase pCASL (MP pCASL) has been
shown to reduce these errors in both humans [29] and rats
[27], but this sequence has not yet been applied in mice. We
have recently implemented a multiphase pCASL method for
use in the rat brain, which shows high reliability, re-
producibility, and accuracy for CBF measurements [27].
However, given the even smaller size of the mouse brain,
implementing this sequence in mice remains challenging.
Movement artefacts from respiration affect the signal at the
base of the brain in particular, and air spaces surrounding
the brain produce distortions. Since most preclinical models
of primary brain tumours and brain metastasis are estab-
lished in mice rather than rats, developing this method
further for robust and reliable application in mice is
essential.
+us, the primary aim of this study was to optimise and
validate MP pCASL MRI for measuring CBF in naı̈ve mice.
Subsequently, we assessed the sensitivity of the optimised
MP pCASL sequence to changes in blood flow in early stage
tumours, using mouse models of secondary brain cancer
(metastasis) and primary glioma.
2. Materials and Methods
2.1. Animals. Female BALB/c mice (Charles River, UK),
7–10 weeks old, were used in all naı̈ve and metastasis model
experiments. Female SCID mice (Charles River, UK), 7–10
weeks old, were used in all primary brain tumour model
experiments. All animal experiments were approved by the
UK Home Office (Animals (Scientific Procedures) Act 1986)
and conducted in accordance with the University of Oxford
Policy on the Use of Animals in Scientific Research and the
ARRIVE guidelines [30]. Animals were housed in in-
dividually ventilated cages under a 12-h light/12-h dark cycle
with food and water ad libitum. All animals were housed in
cages of 4–6 animals.
2.2. Carotid Blood Flow Measurements. Mice (n � 4) were
anaesthetised with 3% isoflurane in O2. Temperature was
monitored and maintained at 37.0 ± 0.5°C throughout with
a feedback heating system. Respiration was monitored and
maintained between 30 and 80 breaths per minute. An
electrocardiogram was also acquired. Using a Vevo 3100
ultrasound (Visualsonics, Amsterdam, Netherlands) and
a mouse cardiology probe (MX550D), a respiration-gated
3D ultrasound image was acquired across the whole neck.
+e left carotid artery was located, and 10 Power Doppler
blood flow clips of 30 s duration were acquired per mouse at
respiration rates across the range of 30–80 breaths per
minute, achieved by varying the concentration of isoflurane
between 3 and 1%. Carotid blood flow values from the Power
Doppler trace were extracted using an open-source plot
digitiser [31], and values representing the systolic and di-
astolic flow velocities were used in pCASL simulations to
determine labelling efficiency.
2.3. Labelling Efficiency Simulations. Bloch simulations were
carried out to simulate labelling efficiency over a range of
different gradient strengths, radiofrequency (RF) powers,
labelling plane thicknesses, and blood flow velocities, as
described by Okell [32]. We conducted Bloch simulations
whilst varying Gmax and Gmean (Gmean � 0.05 × Gmax in our
MP pCASL sequence) gradient strengths, equivalent to
converted labelling plane thicknesses of 1–10mm in 0.5mm
steps. Blood flow velocities of between 1 and 20 cm/s with
steps of 1 cm/s were modelled with T1blood � 2.1 s, T2blood �
0.033 s (based on ex vivo rat blood measurements at 9.4 T)
[27], and RF pulse amplitudes of 1–10 µTwith steps of 0.5 µT
for a train of 600 μs Hanning-shaped pulses, beginning every
1.2ms. Simulations of the theoretical maximum saturation
for different label durations were also carried out, and data
are available in the Supplementary Information.
2.4. MP pCASLOptimisation. MP pCASL experiments were
performed on a separate cohort of mice (n � 4) using a 9.4 T
MRI spectrometer (Agilent Technologies Inc., Santa Clara,
USA) with a 26 mm volume transmit-receive birdcage RF
coil (Rapid Biomedical GmbH, Rimpar, Germany). Mice
were anaesthetised with 3% isoflurane in 30% O2: 70% N2
and positioned in a custom-built cradle in the volume coil.
Mouse temperature was monitored andmaintained at 37.0 ±
0.5°C with a rectal probe and feedback heating system.
Respiration was monitored using a pressure balloon, and
breathing rate was maintained at approximately 60 breaths
per minute by adjusting isoflurane concentration; stable
breathing was typically maintained with an isoflurane
concentration of 1.2–1.5%. +e respiration trace was
recorded and used to inform respiratory triggering.
Zero- and first-order shimming was conductedmanually
using a PRESS sequence on a voxel encompassing the brain.
+e EPI readout was acquired with the following parameters:
2-shot spin-echo encoding, relaxation time (TR) � 4.0 s,
echo time (TE) � 18.32ms, spectral width (SW) � 250 kHz,
field of view (FOV) � 20 × 20mm,matrix size � 64 × 64, slice
thickness � 1mm, and number of slices � 8, with the anterior
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slice positioned just posterior to the olfactory sulcus. Re-
spiratory triggering (with an associated variable post-trigger
delay) was also employed to reduce signal fluctuation at the
base of the brain caused by respiratory motion.
+e MP pCASL parameters were optimised for use in
mice. +e MP pCASL labelling was implemented with
a labelling train consisting of a set of slice-selective
RF/gradient pulse pairs followed by a slice-refocusing gra-
dient pulse; RF pulse duration 600 μs, Hanning shape with
effective flip angle (FA) � 40°, and slice-refocusing gradient
pulse duration 600 μs. +e phase of these RF pulses was
arrayed from 0° to 315° with incremental steps of 45°: 0°, 45°,
90°, 135°, 180°, 225°, 270°, and 315°. +e labelling plane was
oriented at −10° relative to the axial plane in order to be
perpendicular to the carotid and vertebral arteries (Figure 1).
+e labelling pulse train was followed by a gradient crusher
to remove residual transverse magnetisation, a postlabel
delay (PLD) to enable labelled blood water spins to travel to
the brain, and the EPI readout. Using these parameters and
the variable respiration trigger, the duration of the scan
varied from 3 minutes 12 seconds to a maximum of ap-
proximately 5 minutes. Labelling train duration was varied
between 0.4 and 5.0 s (TR increased accordingly from 4–
7.6 s) and PLD between 10 and 1000ms, to optimise the MP
pCASL signal.
2.5. Validation of MP pCASL by Autoradiography. For
comparison of MP pCASL data with gold-standard auto-
radiography CBF measurements, näıve mice (n � 4) were
anaesthetised using the same setup and isoflurane concen-
trations as for MRI described above. MP pCASL was per-
formed on each animal on the day before autoradiography,
owing to restrictions concerning the use of radioisotopes in
certain rooms. Care was taken to ensure breathing rate and
isoflurane concentration, and duration of anaesthesia prior
to measurements was as similar as possible between the ASL
and autoradiography sessions. For the MP pCASL MRI,
a labelling pulse duration of 0.9 s and a postlabel delay of
0.4 s seconds was used with the parameters described above.
Autoradiography was performed using the method de-
scribed by Maeda et al. [19]. Mice were injected in-
traperitoneally with 0.15 µCi of 4-iodo-N-methyl-[14C]
antipyrine (Hartmann Analytic, Germany, specific activity
55mCi/mmol), and 2 minutes later, they were injected
intraperitoneally with an overdose of pentobarbitone then
immersed in isopentane on dry ice until frozen. +e frozen
brain was extracted, and 20 µm sections were collected at
200 µm intervals and dried at 60°C for 10min.+ese sections
were exposed to film for 24 hours alongside calibrated ra-
dioactive standards, and films were scanned (Carestream
Kodak BioMax MR Film; standards: 0–35 µCi/g, ARC; Ex-
pression 10000XL transmittance scanner, Epson, UK).
Scanned films were background subtracted and calibrated
against the standards. Absolute CBF was then calculated
using the equation as described by Sakurada et al. [33]. Blood
sampled from the frozen heart at end-point was used to
calculate the final arterial tracer concentration using auto-
radiography. For calculation of regional CBF values, the
autoradiography images were perspective transformed,
aligned to the MR images, and down-sampled to the same
resolution as the MP pCASL images (64 × 64 pixels).
Subsequently, regional masks were created.
2.6. MP pCASL Data Analysis. ASL data analysis and per-
fusion quantification were performed using a custom ver-
sion of the BASIL toolbox from the FMRIB Software Library
(http://www.fmrib.ox.ac.uk/fsl/BASIL). +e raw multiphase
data were initially fitted to a modified Fermi function [27]
(α � 70, β � 19) to produce a raw phase map. +e phase
values were then smoothed and clustered using supervoxel
clustering [34] to produce regions of interest (ROIs) for each
supervoxel phase cluster. +e raw multiphase data were
combined with the supervoxel ROIs to produce high SNR
means of the optimal phase for each supervoxel. +e high
SNR supervoxel data were then fitted to the Fermi function
again to produce a high-precision phase map, which could
be used to calculate the final CBF map.
Perfusion quantitation was performed according to the
kinetic model of Buxton et al. [35] and calibration with
Oxford_asl [36]. Reference scans acquired without labelling
were used for absolute quantitation of CBF. Detailed
postprocessing methods, including supervoxel clustering,
are described by Larkin et al. [27].
2.7. Mouse Models of Brain Metastasis and Primary Brain
Tumours. Sensitivity of the MP pCASL sequence to changes
in tumour blood flow over time was first assessed in a brain
metastasis model. Female BALB/c mice were anaesthetised
with 3% isoflurane in 30% O2: 70% N2O, and focally
microinjected using a finely drawn glass microcapillary (ca.
75 µm tip diameter) with 5000 4T1-GFP, metastatic murine
mammary carcinoma cells in 0.5 µL sterile saline into the left
striatum (+0.5mm anterior, +2mm lateral, 2.5mm depth
relative to bregma). Mice underwentMRI at day 7 (n � 3), 14
(n � 5), 21 (n � 6), 28 (n � 8), or 35 (n � 6) after tumour
induction; mice were randomly assigned to each time point
group.
To further assess the sensitivity of the MP pCASL
method, a primary brain tumour model was also used.
Female SCIDmice were anaesthetised and injected in the left
striatum, as above, with 5000 U87 human glioma cells. Mice
underwent MRI at day 14 (n � 10) or 28 (n � 6), after tu-
mour induction.
In addition to MP pCASL acquisitions, T1 and T2 maps,
angiography, and T1 and T2 weighted anatomical scans were
acquired for each mouse. Time-of-flight angiography was
acquired with TR � 30ms, TE � 1.78ms, FA � 30°, matrix
size � 128 × 128 × 128, and FOV � 20 × 20 × 30mm. A T1-
weighted spin-echo multislice anatomical scan was acquired
with TR � 0.55 s, TE � 20ms, number of averages � 2, and
matrix size � 256 × 256. A T2-weighted fast spin-echo
multislice anatomical scan was acquired with TR � 3.5 s,
echo spacing � 15ms, effective TE � 60ms, echo train length
� 4, and matrix size � 256 × 256; using the same slice plan
and FOV as the MP pCASL. A contrast-enhanced scan was
obtained 5 minutes following intravenous injection of 30 µL
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(15 µmol, approximately 0.75mmol/kg based on a 20 g
mouse) Gadodiamide (Omniscan, GE Healthcare) using the
T1-weighted scan parameters described above.
Following imaging, mice underwent transcardial
perfusion-xation with 0.9% heparinised saline followed
by 20mL periodate-lysine-paraformaldehyde solution con-
taining 0.025% glutaraldehyde, and the brains were collected
for histology.
2.8. Immunohistochemistry. Sections were stained for the
blood vessel marker CD31 (AF3628, R&D systems,
Abingdon, UK) according to the method described by
Andreou et al. [37]. Microvessel density (vessel area fraction)
was quantied for the core and rim regions of the entire
tumour, and also for the contralateral striatum, as the
percentage of area covered using the “Positive Pixel Count
2004-08-11” algorithm in Imagescope (Leica Biosystems).
­e parameters used for perfusion-xed tumour model
10µm sections were moderately stained pixel intensity be-
tween 202 and 185 and strongly stained pixel intensity lower
than 10. ­e parameters used for postxed 20 µm autora-
diography sections were moderately stained pixel intensity
between 180 and 171, and strongly stained pixel intensity
lower than 53.
2.9. Statistics. All data are reported as group mean ± group
standard deviation. Di¯erences between groups were de-
termined using two-tailed paired t-tests or one-way ANOVA
(regional and histology analysis), or two-way repeated
measures (paired) ANOVA (time-course analysis) followed
post hoc by the Bonferroni multiple test correction. An f-test
was used to assess heterogeneity between groups.
3. Results
3.1.MP pCASL SequenceOptimisation. Blood velocity in the
carotid artery was measured to inform Bloch simulations of
pCASL. ­e mean blood velocity in the carotid artery was
found to be 124 ± 17mm/sec, and the maximum blood
velocity was found to be 275 ± 58mm/sec. Mean blood
velocity was consistent between animals, but varied with the
respiration rate in 3 of 4 animals (linear regression, slope 
0.3–1.4). Maximum blood velocity varied between animals
(range  214–556mm/sec), and also varied with the respi-
ration rate in 3 of 4 animals (linear regression, slope 
2.0–7.6). Using these values to inform the range of blood
velocities in the Bloch simulations, a 2 mm label thickness
was chosen as it provided sucient theoretical inversion
(labelling) eciency (78.5%) at the RF pulse amplitude used
in our system (5 µT) and average blood velocity of 124mm/s,
and lies within the linear portion of the feeding arteries in
the neck.
Respiratory triggering, whereby the EPI readout was
acquired during the plateau phase of respiration, was found
to reduce signal uctuation at the base of the brain (Sup-
plementary Figure 1). ­e respiratory triggering also sig-
nicantly increased the signal-to-noise ratio (SNR) of the
MP pCASL data (15.1 ± 5.9) compared wih the untriggered
sequence (6.5 ± 1.5, p< 0.05; Supplementary Figure 2).
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Figure 1: Optimisation of EPI readout using respiratory triggering to acquire the imaging readout during the plateau phase of respiration,
reducing signal uctuation at the base of the brain. Black trace  raw respiration trace; red trace  digitised respiration trace which acts as the
trigger signal; and blue trace  readout of the post-trigger delay period, followed by the imaging slice acquisition. A variable encoding the
post-trigger delay was implemented in the sequence to allow adjustment for changing respiration rates.
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sequence to allow adjustment for changing respiration rates
in subsequent scans (Figure 1).
Following angiography, a labelling plane positioned at
−10° relative to the axial plane was found to be perpendicular
to the carotid and vertebral arteries. Label placement just
posterior to the medulla oblongata enabled consistent la-
belling plane placement between animals using a distinct
anatomical landmark, and is posterior to the vertebral
flexure of the carotid arteries (Figure 2(a)).
All labelling pulse train durations tested yielded CBF
values close to the physiological range expected from the
literature (Figure 2(b)), and no significant differences in
calculated CBF values were found between the different
durations. Similarly, phase maps were stable across labelling
durations. +us, as a compromise between ensuring suffi-
cient labelling (SNR simulations described in Supplementary
information) and keeping scan time as short as possible,
a label duration of 0.9 s was chosen.
To allow measurement of bolus arrival time in brain
voxels, 12 PLDs from 10 to 1000ms were acquired, each with
8 phases of labelling RF pulses. Arrival maps showed that the
bolus arrived at over 95% of voxels in the most anterior slice
and at 99% of voxels in the most posterior slice within 0.4 s
(Figure 3(c)). +us, 0.4 s was chosen as the optimal PLD to
reduce signal loss from relaxation.
3.1.1. MP pCASL Validation. Use of the optimised MP
pCASL sequence in näıve mice yielded measured CBF values
of 96 ± 18mL/100 g/min on average across the brain
(Figure 4(a)), 103 ± 23mL/100 g/min in the cortex, 90 ±
24mL/100 g/min in the striatum, and 77 ± 21mL/100 g/min
in the corpus callosum. Using the gold-standard auto-
radiography method, we measured CBF to be 101 ±
32mL/100 g/min across the whole brain, a difference of <6%
when compared with MP pCASL results across the same
region (Figure 4(a)). Average CBF values using autoradi-
ography were 102 ± 32mL/100 g/min in the cortex, 95 ±
25mL/100 g/min in the striatum, and 87 ± 28mL/100 g/min
in the corpus callosum. No significant differences were
found between MP pCASL and autoradiography CBF
measurements (Figure 4(b)). Blood vessel density was cal-
culated from histological sections stained for CD31 in these
animals, yielding values of 3.0 ± 0.6%, 2.2 ± 0.8%, and 0.8 ±
0.3% for the cortex, striatum, and corpus callosum, re-
spectively (Supplementary Figure 3). Although both CBF
and vessel density appeared to decrease across the three
regions studied (cortex > striatum > corpus callosum), no
significant correlation between vessel density and CBF was
found.
3.1.2. Mouse Model of Brain Metastasis. Application of the
MP pCASL sequence in mice with intracerebral metastases
showed a significant, 16%, decrease in CBF in the tumour-
bearing striatum (84 ± 16mL/100 g/min) compared with
the contralateral (normal) striatum (99 ± 24mL/100 g/min)
at day 35 (ANOVA p< 0.05; post hoc Bonferroni test
p< 0.05). +e mean absolute reduction in CBF in
the tumour-bearing striatum was 15.3mL/100 g/min. No
differences were found between hemispheres at other time
points. All tumours were confirmed histologically, and the
mean tumour diameter measured by histology at day 35
was 2.14 ± 0.53mm.
In a subset of animals from days 21–35 (n � 7), the
striatum exhibited gadolinium enhancement throughout the
area of metastatic foci and, in these animals, no difference in
CBF was evident between the tumour (86 ± 26mL/100 g/min)
and contralateral striatum (92 ± 24mL/100 g/min; Fig-
ures 5(a)–5(c). Analysis of microvessel density within the
metastatic foci showed an increased vessel area fraction
(7.7 ± 2.2%; Figure 5(d)) in the enhancing tumour com-
pared with normal tissue in the contralateral striatum
(0.9 ± 0.4%, p< 0.0005; Figures 5(e)–5(f )).
However, in a further, distinct subset of animals
from days 28 and 35 (n � 6), a gadolinium-enhancing
tumour rim was evident surrounding a nonenhancing tu-
mour core. Analysis of these animals showed a significant
reduction in blood flow in the core of the tumour region
(69 ± 14mL/100 g/min) compared with the rim (83 ±
10mL/100 g/min, p< 0.05; Figures 6(a)–6(c). No difference
was found between the enhancing rim of the tumour
and normal tissue in the contralateral striatum (82 ±
13mL/100 g/min; Figure 6(c)). +e mean absolute reduc-
tion in CBF in the tumour core compared with that in the
tumour rim was 13.4mL/100 g/min. +e tumour voxels
(including core and rim) showed significantly greater het-
erogeneity, as demonstrated by higher intra-ROI voxel
variance, than the contralateral striatum (F-test, p< 0.001).
Analysis of microvessel density within the metastatic foci
showed a greatly increased vessel area fraction (13.5 ± 2.5%)
in the nonenhancing tumour core compared with the tu-
mour rim (6.6 ± 2.5%, p< 0.0001; Figures 6(d)–6(f )), which
in turn showed greater vessel area fraction than the normal
tissue in the contralateral striatum (1.2 ± 0.7%, p< 0.0001;
Figure 6(f )). Correlation analysis between microvessel
density and CBF measured by MP pCASL MRI revealed
a trend towards negative correlation in both tumour core
and rim, but this did not reach significance (Supplementary
Figure 4).
3.1.3. Mouse Model of Glioma. Application of the MP
pCASL sequence in mice injected intracerebrally with U87
glioma cells showed a significant, 19%, reduction in CBF in
the tumour-bearing striatum (61 ± 12mL/100 g/min)
compared with the contralateral striatum at day 28 (74 ±
10mL/100 g/min, p< 0.05; Figures 7(a)–7(c)). +e mean
absolute reduction in CBF in the tumour-bearing striatum
was 13.3mL/100 g/min. Only two tumours showed gadoli-
nium enhancement, and no tumours showed nonenhancing
core regions. As for the metastasis model, analysis of
microvessel density within the day 28 tumours showed an
increased vessel area fraction (10.7 ± 2.9%; Figure 7(d)) in
the tumour compared with the normal tissue in the con-
tralateral striatum (3.6 ± 0.5%, p< 0.05; Figures 7(e)–7(f )).
All tumours were confirmed histologically, and the mean
tumour diameter measured by histology at day 28 was 1.20 ±
0.52mm.
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Figure 2: Optimisation of MP pCASL bolus duration. (a) A−10° labelling plane (blue) relative to the axial imaging plane (yellow) was
optimal, as this was perpendicular to the carotid and vertebral arteries visible by angiography (red). Label plane placement posterior to the
medulla oblongata, visible on a sagittal T2 weighted anatomical image (green), enabled consistent label plane location between animals,
while not interfering with imaging slices (yellow). (b) No signicant di¯erences were found in calculated CBF across the range of label












































Figure 3: Optimisation of postlabel delay (a–b). Multi-PLD scans were acquired to measure arterial transit time at the front and back of the
brain. Example maps of bolus arrival time in (a) anterior and (b) posterior slices. (c) Arrival maps showed bolus arrival in over 95% of voxels






























































Figure 4: Cerebral blood ow maps and regional values. (a) Representative CBF maps produced using gold-standard autoradiography (top
row), and the optimisedMP pCASL sequence (bottom row). (b) Regional CBF values as measured byMP pCASL and autoradiography (AR).
Average CBF values were 96 ± 18mL/100 g/min across the whole brain using MP pCASL, and 101 ± 32mL/100 g/min using autoradi-
ography. No signicant di¯erences were found between MP pCASL and autoradiography CBF measurements either for whole brain, or by
region. CC–corpus callosum.
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4. Discussion
Pseudocontinuous ASL is the recommended MRI sequence
for clinical measurements of cerebral blood ow, and
multiphase ASL sequences have many advantages in com-
pensating for o¯-resonance e¯ects that alter labelling e-
ciency, thus improving the quality and reliability of CBF
maps produced. Despite these advantages, no studies have
been published implementing multiphase pCASL in mice.
We have now demonstrated that our optimised MP pCASL
sequence provides reliable and accurate measures of CBF in
naı̈ve mice in vivo and is sensitive to changes in tumour
blood ow.
In this study, our aim was to produce MP pCASL
measurements that can be used to obtain CBF maps in mice
that replicate blood ow values obtained using the gold-
standard approach of autoradiography. Our results showed
good concordance with autoradiography and were in accord
with previous autoradiography ndings [19], including
those comparing ASL with autoradiography [22, 27]. As
anticipated, the use of multiphase pCASL reduced the errors
seen in the previous implementation of label-control pCASL
in mice, owing to loss of inversion eciency [12]. As an
alternative to theMP pCASL approach described here, phase
correction can also be applied using prescans [38]. However,
this method requires processing during scan time rather
than post hoc. For this reason, the MP pCASL approach
o¯ers an easier implementation and potentially more time
ecient approach for the measurement of CBF.
­e inclusion of a respiration trigger in the sequence
reduced signal uctuation at the base of the brain and
improved image quality. However, this technique does result
in a variable TR between phase acquisitions. As the TR
becomes longer than the minimum with triggering, it is
expected that there will be no e¯ect on the next acquisition.
Extended TR values of up to 20 s have been tested with this
sequence and have shown no e¯ect on data quality (data not
shown). ­e use of respiratory triggering also relies on
a reasonably stable respiratory cycle, which was reliably
achieved at ∼60 breaths per minute with 1.2–1.5% isourane
concentrations for up to two hours.
Our data show less regional variation in CBF than other
autoradiography studies in mice, which may, at least in
part, reect di¯erences in mouse strain and anaesthetic
regime used [19, 21, 39]. Gaseous anaesthesia, in particular,
is known to have region specic e¯ects on CBF, and in rats
the caudate/putamen shows a much greater (∼70%) in-
crease in CBF than in the cortex (∼20%) under isourane-
anaesthetised conditions compared with awake animals
[23]. Consequently, regional di¯erences in CBF under
isouorane anaesthesia are greatly reduced [23], and it is































































Figure 5: Application of the MP pCASL sequence in mice with intracerebral 4T1-GFP metastatic tumours showing gadolinium en-
hancement. (a) T1-weighted image showing enhancement (dotted outline) of metastatic foci. (b) CBFmaps with the same ROI indicated. (c)
Graph showing CBF values in tumour and contralateral regions; no signicant decrease in perfusion is evident (d-e). Histological
comparison of microvessel area fraction in tumour (d), and contralateral (e) regions. Scale bars  20 µm. (f) Graph showing quantitation of
microvessel area fraction in tumour and contralateral striatum regions; a signicant increase in microvessel area fraction is evident in
tumour compared with normal tissue in the contralateral striatum (n  7). ∗∗∗p< 0.01.
































































































Figure 6: Application of theMP pCASL sequence in mice with intracerebral 4T1-GFPmetastatic tumours showing a gadolinium enhancing
rim and a nonenhancing core region. (a) T1-weighted image showing core (nongadolinium-enhancing central regions; dotted outline) and
rim (gadolinium-enhancing regions; solid outline) of metastatic foci. (b) CBF maps with the same ROIs indicated. (c) Graph showing CBF
values in core, rim, and contralateral regions; a signicant decrease (n  6) in perfusion is evident between the core and rim regions of
tumours (d-e). Histological comparison of microvessel area fraction in core (d) and rim (e) regions. Scale bars  20 µm. (f) Graph showing
quantitation of microvessel area fraction in core, rim, and contralateral striatum regions; a signicant increase in vessel area fraction is



































Figure 7: Application of the MP pCASL sequence in mice with intracerebral U87 glioma at the day 28 time point. (a) T1-weighted image
showing no evidence of gadolinium enhancement in the tumour injected (left) hemisphere. (b) Immunohistochemical image showing an
overlay of tumour area (red) combined from tissue sections spanning 500 µm corresponding to the MRI slice in (a). (c) CBF maps showing
reduction in local CBF (arrowheads) (d-e). Immunohistochemical image showing CD31 staining of vessels (brown) in tumour-injected
striatum (d) and contralateral striatum (e). (f ) Graph showing CBF values in the tumour-bearing (black) and contralateral (white) striatum.
CBF is reduced in the tumour-bearing compared with the contralateral striatum at day 28 time point (p  0.02). Scale bars  20 µm.
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CBF observed in the current study. +e reduced regional
variation was observed in both MP pCASL and autoradi-
ography data, supporting the above conclusion. To reduce
the effects of isoflurane on our CBF measurements, we used
the lowest possible concentration of isoflurane in order to
achieve a stable breathing rate of ∼60 breaths per minute.
+e MP pCASL technique was found to be sensitive to
changes in tumour perfusion in mouse models of both brain
metastasis and glioma at later time points. +e technique was
also sensitive to perfusion heterogeneity within metastatic
tumours, showing significantly reduced (but not absent)
perfusion in the nonenhancing tumour core compared with
normal tissue in the contralateral striatum and increased
heterogeneity in perfusion compared with the contralateral
striatum. As autoradiography has only been used to validate
CBF measurements in the näıve brain, it is possible that
differences in tumour arterial transit time or tissue relaxation
time may affect the CBF quantification from MP pCASL data
in these tumour-bearing animals. However, these results are
in line with other preclinical primary brain tumour perfusion
studies, which showed reduced perfusion in the tumour core
[7, 40–42]. +e reduction in tumour blood flow observed in
the current study was considerably smaller than other (pri-
mary) tumour perfusion studies. +e majority of previous
studies have investigated large tumours (>5mm diameter in
mice) [7, 9, 40, 42], which often have a large necrotic core
with few blood vessels [7, 43] resulting in a substantial
perfusion deficit. In contrast, in both the metastasis and
glioma models used here, the tumour foci were considerably
smaller (1–2mm diameter) and more diffusely growing.
Moreover, histological analysis demonstrated that the core
regions, rather than being necrotic and devoid of vessels, in
fact contained large numbers of blood vessels. Such tumours
would be ideal candidates, clinically, for treatment with
vascular modifying agents, and the ability to quantitatively
measure changes in blood flow in such small tumours could
be of considerable use in preclinical testing.
Tumours have a number of distinct vascular phenotypes,
each of which may confer changes in blood flow. One such
phenotype, which is present in our model, is that of a highly
branched network of nonfunctional angiogenic vessels. In
this case, despite an increase in the density of vessels,
a decrease in CBF may be observed in this region, owing
their highly branched and dysfunctional nature. Another
vascular phenotype often seen in solid tumours is the rapid
growth of the tumour faster than the vasculature can keep
up, resulting in a tumour core with low vascularity, and
hence a decreased CBF. Both of these phenotypes are
characterised by a decrease in CBF, despite the differences in
tumour vascularity.
Gadolinium contrast enhancement on MRI reports on
both vessel permeability and blood flow, and a lack of
gadolinium enhancement in tumour core regions is typically
taken to reflect tissue necrosis and complete absence of
vessels. In contrast, blood vessel density measurements
provide no information on whether vessels are perfused, but
only whether they are present. However, in both models
used in the current study, although core tumour areas
showed significant reductions in blood flow in areas devoid
of gadolinium enhancement, histological assessment
revealed a significant increase in microvessel density and
only very small areas of necrosis. Together, these findings
suggest that these core vessels are either structurally ab-
normal or have abnormal flow patterns, as is common in
angiogenic tumour vessels [44–46], and that MP pCASL
measurements may complement histology and contrast-
enhanced MRI to provide useful insights into vessel pa-
tency and tumour blood flow.
Interestingly, the rim of the metastatic tumour area also
showed an increase in microvessel density histologically, but
in this region, CBF measured by MP pCASL MRI was
normal. Similarly, in those tumours showing enhancement
throughout the tumour core, microvessel density was in-
creased, but no change in CBF was evident. +ese findings
suggest that MP pCASL MRI identifies heterogeneity in
tumour blood flow that could not be predicted from his-
tological assessment of vascularity alone. +us, by identi-
fying areas of reduced (but not absent) flow,MP pCASLMRI
may enable identification of brain tumours in which vascular
normalising therapy or antiangiogenic therapy could be
beneficial prior to, or in conjunction with, radiotherapy.
5. Conclusions
Multiphase pCASL MRI has been successfully implemented
and validated for imaging cerebral blood flow in naı̈ve
mice and has been shown to overcome the limitations in-
herent in standard nonmultiphase ASL methods. +e data
show high reproducibility in CBF measurements between
animals and concordance with gold-standard autoradiog-
raphy measurements. Further, this imaging approach is
sensitive to changes in perfusion in mouse models of both
primary and secondary brain tumours, even in very small
tumours, and provides insight into tissue blood flow dy-
namics that complements vessel density measurements and
contrast-enhanced MRI. +is method could be of high value
for noninvasive measurement of brain tumour blood flow
prior to and following therapy, increasing the potential for
clinical translation.
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Supplementary Materials
Supplementary Figure 1 (video): exampleMP pCASL images
with (A) and without (B) respiratory triggering. Respiratory
triggering reduces signal fluctuation at the base of the brain.
Supplementary Figure 2: signal-to-noise ratio (SNR) of the
MP pCASL sequence with and without respiratory triggering
(n � 4, ∗p< 0.05). Supplementary Figure 3: microvessel
density of brain regions in näıve animals used for autora-
diography (n � 4). ∗p< 0.05; ∗∗p< 0.01 Supplementary
Figure 4: plot showing correlations between CBF and
microvessel density in a subset of animals (n � 6) with
a gadolinium enhancing rim and nonenhancing core
structure. Linear regression lines for each dataset are plotted,
showing a trend towards an inverse correlation between CBF
and microvessel density for core and rim regions. Supple-
mentary Figure 5: change in theoretical signal saturation
over a range of label durations. (Supplementary Materials)
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